Zobrazeno 1 - 10
of 2 076
pro vyhledávání: '"PD‐1 inhibitor"'
Autor:
Jin M, Jiang ZQ, Qin JH, Qin HX, Jiang KW, Ya HX, Gu J, Gui MR, Li YH, Xu LK, Fu HX, Xiao XH, Li SQ
Publikováno v:
Journal of Hepatocellular Carcinoma, Vol Volume 11, Pp 2309-2320 (2024)
Ming Jin,1,* Zhi-qing Jiang,2,* Jia-hui Qin,3,* Hui-xia Qin,4,* Kai-wen Jiang,3,* Hou-xiang Ya,3 Jing Gu,3 Mo-rui Gui,5 Yao-hua Li,3 Long-kuan Xu,6 Hai-xiao Fu,6 Xu-hua Xiao,7 Shu-qun Li3 1Department of Vascular Intervention, Affi
Externí odkaz:
https://doaj.org/article/de755f3d18494613bb0939e02f5709e0
Publikováno v:
JAAD Case Reports, Vol 53, Iss , Pp 170-173 (2024)
Externí odkaz:
https://doaj.org/article/4586b76302344b45a4b47612bce5a77a
Autor:
ChiIeng Tou, LinFeng Ma
Publikováno v:
Radiology Case Reports, Vol 19, Iss 10, Pp 4497-4503 (2024)
Primary mediastinal large B-cell lymphoma (PMBCL) is a specific subtype of diffuse large B-cell lymphoma (DLBCL), which occurs more frequently in young women. PMBCL is an uncommon kind of cancer. R-EPOCH is a common therapeutic regimen that is suitab
Externí odkaz:
https://doaj.org/article/8dfe0799e24e451b96a2b0edbb0e4c4a
Publikováno v:
Journal of Hepatocellular Carcinoma, Vol Volume 11, Pp 1727-1740 (2024)
Ruixia Li,1,* Xiaohui Wang,2,* Hui Li,3 Murong Wang,3 Juncheng Wang,4 Wei Wang,5 Qunfang Zhou6 1Department of Thyroid Surgery, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong Province, People’s Republic of Chin
Externí odkaz:
https://doaj.org/article/c55db1248a1343b09a46fae0af019a83
Publikováno v:
Case Reports in Oncology, Vol 17, Iss 1, Pp 928-934 (2024)
Introduction: Chemotherapy plus immunotherapy is the standard treatment worldwide for advanced lung squamous cell carcinoma with high programmed cell death protein-1 (PD-1) expression. The use of immunotherapy alone against advanced lung squamous cel
Externí odkaz:
https://doaj.org/article/a15215f6c7f64c47a45ebf82e6813ed7
Publikováno v:
ImmunoTargets and Therapy, Vol Volume 13, Pp 399-412 (2024)
Wei Wang,1,* Ruixia Li,2,* Hui Li,3 Murong Wang,3 Juncheng Wang,4 Xiaohui Wang,5 Qunfang Zhou6 1Department of General Surgery, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning, People’s Republic of China; 2Depa
Externí odkaz:
https://doaj.org/article/5f3163c68d2e4371832787acb6119728
Autor:
Evgeny L. Choynzonov, Alexander A. Fedenko, Natalia A. Falaleeva, Tatiana V. Andreeva, Sergei G. Afanas'ev, Zelimkhan A. Bakaev, Danila I. Valiev, Aleksandr A. Volkov, Larisa A. Kolomiets, Tatiana V. Krashikhina, Sergei V. Miller, Viktoriia V. Mikhaliuk, Andrei N. Ogloblin, Svetlana A. Orlova, Stanislav V. Pataliak, Ilya A. Pokataev, Nataliia O. Popova, Olesia V. Rebrina, Rustem N. Safin, Irina Iu. Stradaeva, Iuliia V. Trefilova, Inessa S. Usol'tseva, Evgenii A. Usynin, Sergey V. Sharov, Denis Iu. Iukal'chuk, Aishat R. Iasieva
Publikováno v:
Современная онкология, Vol 26, Iss 2, Pp 173-181 (2024)
Background. Post-registration observational studies with switching therapy from the original drug to a biosimilar for non-medical indications allow us to assess the safety and effectiveness of this type of switching in real clinical practice. Aim.
Externí odkaz:
https://doaj.org/article/d14ddd461b434759b7f775f2404d2a49
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
IntroductionTo assess the efficacy and safety of first-line immunotherapy-containing regimens compared with chemotherapy for advanced or metastatic urothelial carcinoma (UC).MethodA comprehensive search was performed in four databases (Pubmed, Embase
Externí odkaz:
https://doaj.org/article/f415389e3de24a78910edb7c038cbf2b
Publikováno v:
Oral Oncology Reports, Vol 12, Iss , Pp 100652- (2024)
Recent advances in cancer immunotherapy, including immune checkpoint inhibitors (ICIs) and chimeric antigen receptor (CAR) T-cell therapy, have significantly improved the clinical management of various cancers. ICIs, such as PD-1/PD-L1 and CTLA-4 inh
Externí odkaz:
https://doaj.org/article/4bc04bb9fb1a4f209dbf47acb5d8086b
Autor:
Xiaotao Geng, Xiaolong Chang, Xiaoli Wang, Shunjia Li, Guiyan Han, Zhiyu Song, Furong Hao, Jianwen Li
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
BackgroundNuclear protein in testis (NUT) cancers, also known as midline cancers, tends to occur in organs near the midline, such as the nasal sinuses and mediastinum. NUT carcinoma is very rare and has a poor prognosis.Case descriptionWe report the
Externí odkaz:
https://doaj.org/article/7d373766f13148a5b266450007082017